COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis.

ABSTRACT:

Background

In the aftermath of Covid-19, some patients develop a fibrotic lung disease, i.e., post-COVID-19 lung disease (PCLD), for which we currently lack insights into pathogenesis, disease models, or treatment options.

Methods

Using an AI-guided approach, we analyzed > 1000 human lung transcriptomic datasets associated with various lung conditions using two viral pandemic signatures (ViP and sViP) and one covid lung-derived signature. Upon identifying similarities between COVID-19 and idiopathic pulmonary fibrosis (IPF), we subsequently dissected the basis for such similarity from molecular, cytopathic, and immunologic perspectives using a panel of IPF-specific gene signatures, alongside signatures of alveolar type II (AT2) cytopathies and of prognostic monocyte-driven p

SUBMITTER: Sinha S 

PROVIDER: S-EPMC9297827 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature